Publications

 1. Aksoylar S, Aydinok Y, Serdaroglu E, Coker M, Ozdemir F, Ozkinay F: HDR (hypoparathyroidism, sensorineural deafness, renal dysplasia) syndrome presenting with hypocalcemia-induced generalized psoriasis. J Pediatr Endocrinol Metab 2004, 17: 1031-1034.

 2. Aydinok Y, Erermis S, Bukusoglu N, Yilmaz D, Solak U: Psychosocial implications of Thalassemia Major. Pediatr Int 2005, 47: 84-89.

 3. Bilenoglu O, Basak AN, Russell JE: A 3'UTR mutation affects beta-globin expression without altering the stability of its fully processed mRNA. Br J Haematol 2002, 119: 1106-1114.

 4. Borgatti M, Finotti A, Romanelli A, Saviano M, Bianchi N, Lampronti I et al.: Peptide nucleic acids (PNA)-DNA chimeras targeting transcription factors as a tool to modify gene expression. Curr Drug Targets 2004, 5: 735-744.

 5. Canatan D, Karadoan C, Balta N, Oguz N, Cosan R, Cengiz O et al.: Different desferrioxamine usage in the patients with thalassemia major: a cost-effect analysis. Turk J Haematol 2004, 21: 173-176.

 6. Cariolou MA, Kokkofitou A, Manoli P, Christou S, Karagrigoriou A, Middleton L: Underexpression of the apolipoprotein E2 and E4 alleles in the Greek Cypriot population of Cyprus. Genet Epidemiol 1995, 12: 489-497.

 7. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E: Thalassemia. Hematology Am Soc Hematol Educ Program 2004, 14-34.

 8. Davies JK, Telfer P, Cavenagh JD, Foot N, Neat M: Autoimmune cytopenias in the 22q11.2 deletion syndrome. Clin Lab Haematol 2003, 25: 195-197.

 9. Del Vecchio L, Locatelli F: [Innovations in dialytic therapy and daily clinical problems: anemia]. G Ital Nefrol 2004, 21 Suppl 30: S46-S48.

10. Di Filippo S, Manzoni C, Locatelli F: [The use of dialysate conductivity in the sodium and urea kinetic models]. G Ital Nefrol 2004, 21 Suppl 30: S54-S57.

11. Di Giacomo F, Luca F, Anagnou N, Ciavarella G, Corbo RM, Cresta M et al.: Clinal patterns of human Y chromosomal diversity in continental Italy and Greece are dominated by drift and founder effects. Mol Phylogenet Evol 2003, 28: 387-395.

12. Di Giacomo F, Luca F, Popa LO, Akar N, Anagnou N, Banyko J et al.: Y chromosomal haplogroup J as a signature of the post-neolithic colonization of Europe. Hum Genet 2004, 115: 357-371.

13. El Beshlawy A, Ragab L, Fattah AA, Ibrahim IY, Hamdy M, Makhlouf A et al.: Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol 2004, 111: 143-148.

14. El Beshlawy A, Hussein HA, Abou-Elew HH, Abdel Kader MS: Study of protein C, protein S, and antithrombin III in hypoxic newborns. Pediatr Crit Care Med 2004, 5: 163-166.

15. Fattoum S, Messaoud T, Bibi A: Molecular basis of beta-thalassemia in the population of Tunisia. Hemoglobin 2004, 28: 177-187.

16. Fenech AG, Billington CK, Swan C, Richards S, Hunter T, Ebejer MJ et al.: Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol 2004, 30: 678-686.

17. Feriotto G, Finotti A, Volpe P, Treves S, Ferrari S, Angelelli C et al.: Myocyte enhancer factor 2 activates promoter sequences of the human AbetaH-J-J locus, encoding aspartyl-beta-hydroxylase, junctin, and junctate. Mol Cell Biol 2005, 25: 3261-3275.

18. Galanello R, Perseu L, Perra C, Maccioni L, Barella S, Longinotti M et al.: Somatic deletion of the normal beta-globin gene leading to thalassaemia intermedia in heterozygous beta-thalassaemic patients. Br J Haematol 2004, 127: 604-606.

19. Giordano PC, Bouva MJ, Harteveld CL: A confidential inquiry estimating the number of patients affected with sickle cell disease and thalassemia major confirms the need for a prevention strategy in the Netherlands. Hemoglobin 2004, 28: 287-296.

20. Gohari LH, Petrou M, Felekis X, Christopoulos G, Kleanthous M: Identification of alpha-thalassemia mutations in Iranian individuals with abnormal hematological indices and normal Hb A2. Hemoglobin 2003, 27: 129-132.

21. Goldberg Z, Levav Y, Krichevsky S, Fibach E, Haupt Y: Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 2004, 3: 1188-1195.

22. Grinberg L, Fibach E, Amer J, Atlas D: N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic Biol Med 2005, 38: 136-145.

23. Karvounis HI, Zaglavara TA, Parharidis GE, Nouskas IG, Hassapopoulou EP, Gemitzis KD et al.: An angiotensin-converting enzyme inhibitor improves left ventricular systolic and diastolic function in transfusion-dependent patients with beta-thalassemia major. Am Heart J 2001, 141: 281.

24. Kitsiou-Tzeli S, Kolialexi A, Fryssira H, Galla-Voumvouraki A, Salavoura K, Kanariou M et al.: Detection of 22q11.2 deletion among 139 patients with Di George/Velocardiofacial syndrome features. In Vivo 2004, 18: 603-608.

25. Kyriacou K, Kyrri A, Kalogirou E, Vasiliades P, Angastiniotis M, Ioannou PA et al.: Hb Bart's levels in cord blood and alpha-thalassemia mutations in Cyprus. Hemoglobin 2000, 24: 171-180.

26. Kyrri A, Felekis X, Kalogerou E, Christopoulos G, Makariou C, Loizidou D et al.: Hb Limassol [beta8(A5)Lys-->Asn]: a new hemoglobin variant. Hemoglobin 2001, 25: 421-424.

27. Makhoul NJ, Wells RS, Kaspar H, Shbaklo H, Taher A, Chakar N et al.: Genetic heterogeneity of Beta thalassemia in Lebanon reflects historic and recent population migration. Ann Hum Genet 2005, 69: 55-66.

28. Medici J, Wettinger S, Scerri C, Grochowska A, Felice AE: Comparative frequency of coagulation factor II and coagulation factor V alleles among new-born and senior citizens. Malta Med J 2006, 17: 20-27.

29. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000, 355: 2051-2052.

30. Modell B, Khan M, Darlison M, King A, Layton M, Old J et al.: A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ 2001, 79: 1006-1013.

31. New HV, Cale CM, Tischkowitz M, Jones A, Telfer P, Veys P et al.: Nijmegen breakage syndrome diagnosed as Fanconi anaemia. Pediatr Blood Cancer 2005, 44: 494-499.

32. Old J: Haematological Applications: Hemoglobinopathies. In Methods in Molecular Medicine: Molecular Diagnosis of Genetic Diseases. Edited by Mountford R, Elles R. Totowa NJ: Humana Press Inc.; 2004:203-219.

33. Oren H, Devecioglu O, Ertem M, Vergin C, Kavakli K, Meral A et al.: Analysis of pediatric thrombotic patients in Turkey. Pediatr Hematol Oncol 2004, 21: 573-583.

34. Otrock ZK, Mahfouz RA, Taher AT: Should we screen Eastern Mediterranean sickle beta-thalassemia patients for inherited thrombophilia? J Thromb Haemost 2005, 3: 599-600.

35. Parera MC, van Dooren M, van Kempen M, de Krijger R, Grosveld F, Tibboel D et al.: Distal angiogenesis: a new concept for lung vascular morphogenesis. Am J Physiol Lung Cell Mol Physiol 2005, 288: L141-L149.

36. Patrinos GP, de Krom M, de Boer E, Langeveld A, Imam AM, Strouboulis J et al.: Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes Dev 2004, 18: 1495-1509.

37. Patrinos GP, Wajcman H: Recording human globin gene variation. Hemoglobin 2004, 28: v-vii.

38. Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP et al.: Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res 2004, 32: D537-D541.

39. Ropero P, Murga MJ, Gonzalez FA, Polo M, Benavente C, Salvador M et al.: The first case of Hb E-Saskatoon associated with Hb Lepore-Baltimore found in Spain. Hemoglobin 2005, 29: 215-219.

40. Ropero P, Villegas A, Martinez M, Ataulfo Gonzalez FF, Benavente C, Mateo M: A deletion of 11 bp (CD 131-134) in exon 3 of the beta-globin gene produces the phenotype of inclusion body beta-thalassemia. Ann Hematol 2005, 84: 584-587.

41. Santoro N, Giordano P, Del Vecchio GC, Guido G, Rizzari C, Varotto S et al.: Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study. J Pediatr Hematol Oncol 2005, 27: 153-157.

42. Siala H, Fattoum S, Messaoud T, Ouali F, Gerard N, Krishnamoorthy R: A novel alpha-thalassemia nonsense mutation in codon 23 of the alpha2-globin gene (GAG-->TAG) in a Tunisian family. Hemoglobin 2004, 28: 249-254.

43. Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M: Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab 1998, 11 Suppl 3: 935-943.

44. Stankov K, Pastore A, Toschi L, McKay J, Lesueur F, Kraimps JL et al.: Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors. Int J Cancer 2004, 111: 463-467.

45. Tadmouri GO, Garguier N, Demont J, Perrin P, Basak AN: History and origin of beta-thalassemia in Turkey: sequence haplotype diversity of beta-globin genes. Hum Biol 2001, 73: 661-674.

46. Talmaci R, Gavrila L: Detection of β-thalassemia alleles by the ARMS-PCR method in Romania. Romanian Biotechnol Lett 2003, 8: 1241-1246.

47. Talmaci R, Traeger-Synodinos J, Kanavakis E, Coriu D, Colita D, Gavrila L: Scanning of beta-globin gene for identification of beta-thalassemia mutation in Romanian population. J Cell Mol Med 2004, 8: 232-240.

48. Thiebault K, Mazelin L, Pays L, Llambi F, Joly MO, Scoazec JY et al.: The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci U S A 2003, 100: 4173-4178.

49. Tsakris A, Hassapopoulou H, Skoura L, Pournaras S, Douboyas J: Leg ulcer due to Pseudomanas luteola in a patient with sickle cell disease. Diagn Microbiol Infect Dis 2002, 42: 141-143.

50. Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A et al.: Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004, 126: 736-742.